Developmental Research Program

发展研究计划

• 批准号: 7448834
• 负责人: PAUL A. BUNN
• 金额: $ 4.59万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-05-01 至 2013-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7448834
• 关键词: Biological Markers; Cancer Burden; Chemoprevention; Collaborations; Colorado; Committee Members; Comprehensive Cancer Center; Development; Early Detection Research Network; Faculty; Funding; Grant; Institutes; Institution; Malignant neoplasm of lung; Medical Research; Numbers; Outcome; Pediatric Hospitals; Pilot Projects; Purpose; Reporting; Reproduction spores; Request for Applications; Research; Research Personnel; Resources; Score; Translational Research; United States National Institutes of Health; Universities; follower of religion Jewish; genetic epidemiology; innovation; programs; success

The purpose of the Developmental Research Program is to promote the exploration of innovative ideas in translational research in lung cancer through the funding of pilot projects. Each year new pilot project applications are sought by the Developmental Research Committee, which is chaired by Dr. Bunn. Current committee members include Drs. Drabkin, Heasley, Franklin, Hirsch, Baron, and Keith. A request for application announcement is distributed to faculty at all consortium institutions of the University of Colorado Comprehensive Cancer Center (UCDHSC, CU-Boulder, Colorado State University, National Jewish Medical and Research Center, and The Children's Hospital). On average, 11 applications are received each year. The committee scores each application on its novelty, its likelihood of impacting the lung cancer burden through translational research, on its scientific merit, and on the qualifications of the investigators. The use of SPORE resources and the inclusion of collaborations with existing SPORE projects is also taken into consideration. Generally two applications are funded each year at a level of $50,000 each. Half of the support comes from SPORE funds and half comes from institutional funds. In some instances we have provided partial funding for worthy projects that could get started with more limited support. During the recent funding cycle we supported a total of 12 pilot projects. These projects and their outcomes are summarized in the following report. The success of our Developmental Research Program is demonstrated by the progression of a number of recent pilot projects into full SPORE projects. In this competitive renewal, Project 3 originated as a pilot project. As well, progress on the pilot projects of Dr. Heasley, of Dr. Meyer and of Drs. Solomon, Hansen and Duncan have been incorporated into the aims of Projects 2, 3 and 4, respectively. Pilot projects held by Drs. Nemenoff, Heasley, and Malkinson have led to current NCI R01s; the pilot project of Dr. Su has led to an NIH R21; and the pilot projects of Drs. Espinosa and Schiemann are incorporated into their NCI R01s. The research results from projects held by Drs. Franklin and Varella- Garcia were used to renew the NCI EDRN grant in 2005. As well, the Genetic Epidemiology Lung Cancer Consortium (GELCC) and the Lung Cancer Biomarkers & Chemoprevention Consortium (LCBCC) studies were also outcomes of SPORE pilot projects. Several other important lung cancer grants have been funded by other institutes and are described in this report.

发展研究计划的目的是促进对创新思想的探索 通过试点项目的资助，肺癌的转化研究。每年新的试点项目 发展研究委员会寻求申请，该委员会由Bunn博士主持。当前的 委员会成员包括博士。 Drabkin，Heasley，Franklin，Hirsch，Baron和Keith。请求 申请公告已分发给科罗拉多大学所有财团机构的教师 综合癌症中心（UCDHSC，Cu-Boulder，科罗拉多州立大学，国家犹太医学 和研究中心，以及儿童医院）。平均每年收到11个申请。 委员会在新颖性上分数每种应用，影响肺癌负担的可能性 通过翻译研究，科学优点以及研究人员的资格。使用 孢子资源以及与现有孢子项目的合作还包括在内 考虑。通常，每年有两个申请的资金为50,000美元。一半 支持来自孢子资金，一半来自机构资金。在某些情况下，我们有 为有价值的项目提供了部分资金，这些项目可以从更有限的支持下开始。在 最近的资金周期我们总共支持了12个试点项目。这些项目及其结果是 在以下报告中进行了总结。证明了我们的发展研究计划的成功 通过许多最近的试点项目的发展，孢子项目。在这种竞争性更新中 项目3起源于试点项目。同样，迈耶博士Heasley博士的试点项目的进展 和博士。所罗门，汉森和邓肯已被纳入项目2、3和4的目标 分别。 Drs持有的试点项目。 Nemenoff，Heasley和Malkinson导致了当前的NCI R01； SU博士的试点项目导致了NIH R21；以及Drs的试点项目。 Espinosa和Schiemann是 并入其NCI R01。研究结果来自博士持有的项目。富兰克林和瓦拉 - Garcia在2005年也用于续签NCI EDRN Grant。 财团（GELCC）和肺癌生物标志物与化学预防财团（LCBCC）研究 也是孢子试点项目的结果。其他几个重要的肺癌补助也得到了资助 由其他机构进行，并在本报告中进行了描述。